Physician profile
Michael Contento
NPI 1295358646
$1,800.61
in general payments reported to CMS, 2019-2025
14 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.75 · 2021: $237 · 2022: $579 · 2023: $520 · 2024: $96.43 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.86 | 2022-2023 | Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $250.48 | 2023-2025 | Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $218.97 | 2021-2023 | |
| Oyster Point Pharma, INC. | $206.47 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $189.44 | 2021 | |
| Sight Sciences, INC. | $165.30 | 2022-2023 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $122.48 | 2020-2025 | Cequa |
| Alcon Vision LLC | $39.89 | 2021-2025 | Eysuvis |
| Coopervision INC. | $31.07 | 2022 | |
| Harrow Eye, LLC | $30.56 | 2025 | Vevye |
| Dompe US, INC. | $25.34 | 2024 | Oxervate |
| Amgen INC. | $19.99 | 2024 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $18.78 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Contento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.